Idiopathic pulmonary fibrosis (IPF) treatment underwent a paradigm shift after all clinical trials of anti-inflammatory and immunosuppressive agents for IPF failed [1]. Current primary IPF treatment is antifibrotic agents. Although immunity and inflammation may not be as important in the pathogenesis of IPF as previously thought, the involvement of innate and adaptive immunity in IPF continues to be reported. Among innate immune cells, macrophages are thought to be the most important cells in fibrotic lung disease [2]. Neutrophils also play roles in fibrotic lung diseases. Neutrophil elastase is involved in extracellular matrix turnover [3], as well as the proliferation of lung fibroblasts and myofibroblast differentiation [4]. And neutrophils participate in the pathogenesis of IPF by controlling the balance of matrix metalloproteinases and tissue inhibitors of metalloproteinases. The neutrophil chemoattractant interleukin 8 and extracellular neutrophil traps are also associated with pulmonary fibrosis [5]. Bronchoalveolar lavage fluid (BALF) lymphocytosis and eosinophilia help differentiate interstitial lung diseases, such as hypersensitivity pneumonitis and eosinophilic pneumonia, from IPF. However, there have been conflicting reports about the significance of BALF neutrophilia. In a retrospective study of fibrotic nonspecific interstitial pneumonia  and usual interstitial pneumonia (UIP) patients, the BALF findings did not discriminate between the two entities [6]. In another study, BALF neutrophilia was not significantly related to the survival of IPF patients [7]. However, contradictory results have also been reported. In a cohort of 156 patients with IPF, a high percentage of BALF neutrophils was an independent predictor of early mortality [8]. Recently published data have shown that blood neutrophilia is associated with a decline in forced vital capacity and all-cause mortality in IPF [9], and with progression to IPF in patients with an indeterminate computed tomography pattern for UIP [10]. Although aberrant wound healing is the most important mechanism, the pathogenesis of IPF is highly complex and poorly understood. Multiple factors, including aberrant wound healing and immune mechanisms, are thought to be involved. Lee et al. reported that granulocyte colony-stimulating factor (G-CSF) concentrations were higher in BALF from IPF patients than normal controls. The survival rate of IPF patients was significantly lower in the higher G-CSF concentration group, and the BALF neutrophil count was positively correlated with the G-CSF concentration [11]. This result demonstrates the role of innate immunity in the pathogenesis of IPF. No single drug is capable of curing or stopping the progression of IPF. Combination therapy targeting multiple sites of IPF pathogenesis may be more effective than monotherapy. Innate immunity can be a target for IPF treatment, including via neutrophils. However, although neutrophils could promote lung fibrosis, their recruitment to the fibrotic lung may restore homeostasis [5]. Thus, further studies on the role of neutrophils, as “friend or foe,” in pulmonary fibrosis are needed. Conflict of interest

No potential conflict of interest relevant to this article was reported.

REFERENCES 1. Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J 2017;50:1701209.

2. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity 2016;44:450–462.

3. Chua F, Dunsmore SE, Clingen PH, et al. Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis. Am J Pathol 2007;170:65–74.

4. Gregory AD, Kliment CR, Metz HE, et al. Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis. J Leukoc Biol 2015;98:143–152.

5. Ishikawa G, Liu A, Herzog EL. Evolving perspectives on innate immune mechanisms of IPF. Front Mol Biosci 2021;8:676569.

6. Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003;22:239–244.

7. Tabuena RP, Nagai S, Tsutsumi T, et al. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 2005;72:490–498.

8. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008;133:226–232.

9. Achaiah A, Rathnapala A, Pereira A, et al. Neutrophil lymphocyte ratio as an indicator for disease progression in idiopathic pulmonary fibrosis. BMJ Open Respir Res 2022;9:e001202.

10. Achaiah A, Rathnapala A, Pereira A, et al. Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern. BMJ Open Respir Res 2021;8:e000899.

11. Lee JU, Choi JS, Kim MK, Min SA, Park JS, Park CS. Granulocyte colony-stimulating factor in bronchoalveolar lavage fluid is a potential biomarker for prognostic prediction of idiopathic pulmonary fibrosis. Korean J Intern Med 2022;37:979–988.